FIELD: medicine. SUBSTANCE: method involves introducing labeled antibodies or labeled alpha-fetoprotein into biological patient sample to enable labeled antibodies or labeled alpha-fetoprotein to enter into reaction with alpha-protein receptor in the biological sample. Binding alpha-protein receptor sides are determined in the biological material at the next stage having entered into reaction with labeled antibodies or alpha-protein for detecting cancer. It is advantageous to examine the biological patient sample before the introduction stage. One stage of the method is alpha-fetoprotein receptor antibody introduction into the patient cells affected with cancer. Then, the stage of reaction of alpha-fetoprotein receptor antibodies to alpha-fetoprotein receptor of the patient cells affected with cancer follows for inhibiting growth of the cells affected with cancer or necrosis of the cells affected with cancer. Method of patient observation and cancer treatment is also described. Then, a test stage follows. The tests are performed in predefined moments of time after treatment for determining alpha- fetoprotein receptor sizes. EFFECT: enhanced effectiveness of diagnosis and treatment method. 24 cl, 10 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
NEW CANCER ANTIGEN FOR EARLY DETECTION OF CANCER, METHOD FOR OBTAINING, ISOLATION AND DETECTION THEREOF | 2020 |
|
RU2818471C2 |
METHOD FOR PRODUCING ACTIVE FRAGMENT OF HUMAN ALPHA-FETOPROTEIN | 2010 |
|
RU2448116C2 |
METHOD OF PREPARING PREPARATION FOR DIRECTED DELIVERY OF ANTITUMOR DRUG IN CANCER CELL | 1998 |
|
RU2139083C1 |
METHODS OF FORECASTING AND PREDICTION OF CANCER AND CONTROL ON THERAPY OF CANCER | 2006 |
|
RU2395090C2 |
COMPOSITION OF ALPHA-FETOPROTEIN AND APOPTOSIS INDUCTORS FOR CANCER TREATMENT | 2006 |
|
RU2438695C2 |
CANCER DETECTION BY HIGH BCL-2 LEVELS | 2007 |
|
RU2436098C2 |
ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
METHOD OF OBTAINING RADIOLABELLED WITH RADIONUCLIDES ALPHA-FETOPROTEIN IODINE AND METHOD OF ITS IMPLEMENTATION FOR DIAGNOSTICS OF MALIGNANT TUMORS | 2009 |
|
RU2404812C1 |
IMMUNOSTIMULATORY MONOCLONAL ANTIBODIES | 1995 |
|
RU2155190C2 |
METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
Authors
Dates
2000-12-27—Published
1995-09-18—Filed